3 March 2015BiotechnologyLaura von Hertzen and Robert Burrows
Stem cells: A germ of comfort
Stem cell research is advancing at an incredibly fast pace. Technology based on the use of human embryonic stem cells (hESCs) is being employed in an attempt to tackle a wide variety of conditions including vision loss, diabetes, heart disease and skin disorders. However, with such cutting-edge research comes moral considerations, which in turn have implications for the type of technology that
is patentable.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
22 October 2025 Chuck Scholtz, head of IP at Verdiva Bio, shares the pressures of global filing strategies on tight budgets, why there’s no ‘right way’ to manage IP, and how to get the best results from external counsel relationships.
2 September 2025 Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.
12 June 2025 Judges uphold PTAB’s finding that two Agilent patents are invalid | All claims of patents, which cover guide RNAs, found to be anticipated by prior art.